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Abstract:  Retroviruses  are  evolutionary  optimized  gene  carriers  that  have  naturally 
adapted to their hosts to efficiently deliver their nucleic acids into the target cell chromatin, 
thereby overcoming natural cellular barriers. Here we will review—starting with a deeper 
look into retroviral biology—how Murine Leukemia Virus (MLV), a simple gammaretrovirus, 
can be converted into an efficient vehicle of genetic therapeutics. Furthermore, we will 
describe how more rational vector backbones can be designed and how these so-called  
self-inactivating vectors can be pseudotyped and produced. Finally, we will provide an 
overview on existing clinical trials and how biosafety can be improved.  
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1. Introduction 
Retroviral vectors are fascinating and efficient delivery tools for the transfer of nucleic acids. As a 
hallmark, all retroviruses are capable of reverse transcribing their single stranded RNA genome into 
double stranded DNA, which will be stably integrated into the host cell genome [1]. As highly evolved 
parasites they act in concert with cellular host factors to deliver their nucleic acid into the nucleus, 
where they exploit the host cell’s machinery for their own replication and long-term expression occurs. 
The first approaches of retrovirus-based gene transfer were initiated almost 30 years ago [2–9] giving 
first  evidence  that  retroviral  gene  delivery  is  far  more  efficient  than  DNA  transfection  and  that 
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retroviral gene transfer can be used in a murine bone marrow transplantation model. This paved the 
way  for  further  developments  in  gene  therapy  of  the  hematopoietic  system  to  correct  inborn  or 
acquired diseases of the blood and immune system.  
During the past 30 years, the biology of the family of the Retroviridae has become much better 
understood. This knowledge allows the rational design of retroviral vectors for specific applications, 
creating not only more efficient but also safer vector tools. Retroviral vectors have been designed 
based  on  various  members  of  the  Retroviridae  including  Foamyvirus  [10,11],  Human 
Immunodeficiency  Virus  (HIV-1)  [12,13],  Simian  Immunodeficiency  Virus  (SIV)  [14],  Bovine 
Immunodeficiency Virus [15], Feline Immunodeficiency Virus [16], Equine Infectious Anemia Virus 
(EIAV) [17], Murine Leukemia Virus (MLV), Bovine Leukemia Virus [18], Rous Sarcoma Virus 
(RSV) [19,20], Spleen Necrosis Virus (SNV) [21], and Mouse Mammary Tumor Virus [22]. 
While the other reviews in this Special Issue will cover developments in Foamyvirus-derived and 
HIV-1 derived lentiviral vectors, this paper will focus on gammaretroviral vectors based on the simple 
organized  MLV.  We  will  summarize  the  recent  developments  and  build  a  bridge  from  retroviral 
biology and vector design to clinical trials. Furthermore, we will give an overview on safety aspects 
and discuss which steps need to be taken to further improve efficacy and safety of this vector family.  
2. The Retroviral Genome and Particle Organization 
The  development  of  gene  therapy  vectors  originating  from  pathogenic  viruses  could  only  be 
achieved with deeper insight into their biology, starting with the understanding of genome structure, 
particle composition and the retroviral life cycle as exemplified for MLV (reviewed in [23,24]). 
The reverse transcribed and integrated proviral DNA of MLV is flanked by two ―incomplete‖ long 
terminal  repeats  (LTR)  which  are  normally  structured  into  U3,  R  and  U5  (Figure  1).  Since 
transcription of the proviral DNA is initiated by the enhancer-promoter located in the 5’ U3 region, the 
viral genomic RNA starts with R, and is followed by U5, the primer binding site (PBS) for initiation of 
reverse transcription, the major splice donor (SD) and the packaging and RNA dimerization signal (, 
all located upstream of the translational start codon of Gag/Pol (encoding structural and replication 
proteins). Downstream of the gag/pol coding region the env (encoding the viral glycoproteins) reading 
frame is found, whose expression is enabled by a splice acceptor located in pol. The 3’ untranslated 
region of the RNA contains the polypurine tract (PPT), and the 3’ ―incomplete LTR‖ consisting of the 
3’ U3, and the 3’ R region. The latter contains the polyadenylation signal and is thus followed by a 
polyA tail. Since genomic viral RNA carries a 5’ cap and a 3’ pA tail, it resembles a cellular mRNA. It 
is only due to the unique mechanism of reverse transcription that the complete LTRs are restored prior 
to integration of the virus into the host cell chromatin. 
The location of downstream of the major splice donor makes sure that unspliced genomic RNA 
preferentially  associates  with  viral  structural  proteins  for  packaging  into  budding  particles,  while 
spliced subgenomic RNA lacking  can only be translated into envelope proteins. Typically more than 
50% of the viral transcript is expressed as the unspliced full-length species. Alternative splicing in 
MLV is regulated at the level of the major splice donor: experimental data support a model according 
to which a complex RNA secondary structure (stable stem loop structure) is formed upstream of the 
major splice donor which synergizes with suboptimal duplex formation between U1 snRNA and the Viruses 2011, 3                         
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major splice donor to attenuate the splicing process [25,26]; in contrast to complex lentiviruses, the 
splice acceptor upstream of the Env reading frame plays a minor role in the regulation of balanced 
splicing in MLV.  
Figure  1.  Proviral  genome  structure  of  the  Murine  Leukemia  Virus  (MLV),  a  simple 
retrovirus. Indicated are the 5’ and 3’ long terminal repeat (LTR; open boxes) regions 
comprising U3, R and U5, as well as open reading frames (filled boxes) for gag, pol and 
envelope (env) proteins. Processed protein subunits are indicated in bold. att, attachment 
site; cap, 5’RNA capping site; pA, polyadenylation site; PBS, primer binding site; SD, 
splice donor; , packaging signal; SA, splice acceptor; PPT, polypurine tract; MA, matrix; 
CA, capsid; NC, nucleocapsid; PR, protease; RT, reverse transcriptase; IN, integrase; SU, 
surface; TM, trans-membrane; E, enhancer; P, promoter. 
 
 
All Retroviridae contain open reading frames encoding for structural (group associated antigen, 
gag), replication (pol) and envelope (env) proteins which need to assemble in predefined ratios, and 
require  proteolytic  processing  to  form  infectious  particles.  MLV  Gag  is  cleaved  during  particle 
maturation by the retroviral protease into matrix, capsid, p12 and nucleocapsid, and similarly Pol into 
protease, reverse transcriptase and integrase. In contrast, Env as a bipartite transmembrane protein is 
cleaved by furin within the golgi apparatus while being trafficked to the cell surface [27,28]. 
Once the virus particle is detached from its host cell, it resembles an enveloped ribonucleoprotein 
complex that is coated by a packaging cell derived lipid bilayer and envelope proteins. Matrix proteins 
form a ring-like structure underneath the viral membrane to assist anchorage of envelope proteins as 
well as targeting of Gag and Gag/Pol precursor into the budding virus. This outer layer disassembles 
early after cell entry and releases the viral core into the cell cytoplasm. The core is formed by a stable 
capsid lattice which protects the viral genome from degradation and thus forms the environment for 
reverse  transcription  and  assists  subsequent  access  of  the  pre-integration  complex  (PIC)  to  the 
chromatin of the target cell as depicted below.  
2.1. The Early and Late Phase of the Gammaretroviral Life Cycle 
The viral life cycle is divided into an early and a late phase (Figure 2). The early phase begins with 
the binding of viral envelope molecules to receptors on the target cell surface, which ultimately defines 
the target cell tropism of the virus. The interaction will trigger conformational changes in the envelope 
proteins that lead to entry of the virus core into the cell cytoplasm either via fusion of the viral and 
cellular lipid membranes or by transition through the endosome [29,30]. In both cases the viral RNA 
genome  will  be  reverse  transcribed  into its  double stranded  DNA intermediate  within the reverse 
transcription complex (RTC) comprising the dimeric RNA genome, capsid, p12, nucleocapsid, reverse 
transcriptase, and integrase in conjunction with cellular proteins [31,32]. It has been suggested that the Viruses 2011, 3                         
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two copies of the single stranded RNA genome serve as a fail-safe mechanism for production of 
genomic DNA since defects in one strand can be compensated by using the other strand as a template 
[33,34]. Alternatively, or in addition, interstrand recombinations can increase the retroviral genome 
diversity. After formation of the proviral DNA, access to the host cell chromatin is, in case of HIV, 
mediated by interacting with components of the host cell nuclear import machinery (e.g., TNPO3, 
RANBP2) [13,14], further facilitated by the presence of complementary nucleophilic elements [35].  
In  addition,  the  instability  of  the  lentiviral  capsid  [36–38]  as  well  as  resistance  against  cellular 
restriction factors [39] support the transduction of cells independent of their cell cycle status. Since 
MLV  lacks  active  nuclear  import  elements  and  is  encapsulated  by a  highly stable capsid  core,  it 
depends  on nuclear envelope  breakdown and  progression through mitosis in the early phase after 
transduction [40–42]. 
Figure 2. The retroviral life cycle exemplified for MLV. The retroviral particle binds with 
its envelope to cognate receptors on the target cell surface, which facilitates entry of the 
virus core into the cell cytoplasm. After reverse transcription, viral DNA is integrated into 
the host cell chromatin, transcribed, and translated into viral proteins that assemble and 
bud from the plasma membrane to complete the life cycle with extracellular maturation. 
RT, reverse transcription; vRNA, viral RNA. 
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The integration of the viral genome is mediated by the PIC constituted from integrase, capsid, p12 
and proviral DNA, as well as, host cell proteins [43–45]. One such protein, barrier to autointegration 
(Baf), prevents the intramolecular strand transfer by binding to double-stranded DNA and thus shifts 
the reaction towards productive integration which is mediated by the retroviral integrase protein in 
concert with cellular cofactors [46–49]. Since Baf is also found in the PIC of HIV [50], it likely plays a 
conserved role for retroviral integration. The retroviral integration reaction is a three step mechanism: 
(I) The invariant CA dinucleotide at the 5’ and 3’ LTRs is removed from the 3’ strand (3’ processing), 
(II) integrase mediates the strand transfer between 3’ viral DNA and cleaves cellular genomic DNA, 
and  (III)  cellular  DNA  repair  proteins  remove  the  two  unpaired  nucleotides  from  the  LTRs  and 
covalently join free DNA ends between both genomes which finalizes stable integration (reviewed  
in [51]). 
Once proviral DNA is anchored within the host cell chromatin, the ―late phase‖ of viral replication 
begins  with  the  expression  of  viral  RNA  from  the  5’  U3  region.  Viral  RNA  can  either  remain 
unspliced, which results in full length RNA serving for genome replication as well as template for 
Gag/Pol translation, or can be subjected to splicing between the major splice donor and acceptor sites 
located in the leader and the end of pol, respectively. The presence of incompletely processed splice 
signals on cellular mRNA leads to nuclear retention as a means of quality control which required 
retroviruses  to  evolve  alternative  export  strategies  harnessing  various  cellular  export  routes.  The 
―constitutive  transport  element‖  (CTE)  of  Mason  Pfizer  Monkey  virus  binds  to  the  cellular  RNA 
export factor Tap, and HIV’s Rev responsive element (RRE)—Rev interaction hijacks the protein 
export machinery via binding to Crm-1 [52–54]. Despite a genome size of only about 10 kb, such 
export elements have not yet been identified in MLV. Experiments with engineered viral genomes 
suggest that nuclear egress must be independent from gag/pol, env and 3’ U3, and thus must be located 
elsewhere [25,55,56]. Regardless of the presence of one long open reading frame encoding for gag and 
pol, viral particles contain ~10- to 20-fold more gag than pol derived proteins which is crucial for 
infectivity  [57].  In  the  case  of  MLV,  in  5–10%  of  transcripts  a  stop  codon  at  the  end  of  gag  is 
misinterpreted by the translation machinery as glutamine (read-through suppression), and results in a 
read-through  fusion  protein  [58–60]:  Gag/Pol,  which  is  transported  and  anchored  to  the  plasma 
membrane via a myristoylation site in the matrix protein [61,62]. Subsequently, membrane localized 
Gag and Gag/Pol molecules as well as transmembrane envelope proteins assemble at privileged sites 
of the plasma membrane, so-called ―lipid rafts‖, which are of transient nature and rich in cholesterol, 
sphingolipids  and  phosphoglycerides  [63,64].  After  assembly,  viral  particles,  still  containing 
uncleaved  structural  and  replication  proteins,  will  bud  from  the  plasma  membrane,  and  during 
subsequent maturation steps, initiated from the viral protease, will mature into functional monomers of 
the infectious particle before the replication cycle can start again. 
3. How to Turn an Infectious Virus into a Vehicle for Delivery of Genetic Therapeutics 
Due  to  the  potential  of  retroviruses  to  utilize  receptor  mediated  transduction  of  their  genetic 
information into a variety of somatic cells (e.g., embryonic stem cells, hematopoietic and neural stem 
cells),  special  interest  evolved  to  harness  these  mechanisms  for  therapeutic  intervention  and  the 
treatment of (mono)genetic diseases. By inserting the gene of interest (GOI, transgene) within the Viruses 2011, 3                         
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retroviral genome and by employing all retroviral proteins necessary for successful infection, retroviral 
particles serve as well evolved and specialized ―gene ferries‖. To take advantage of a virus for vector 
development and to avoid the generation of replication competent retrovirus (RCR) in gene-modified 
cells, it is necessary to separate genes encoding for structural and enzymatic proteins (Gag/Pol), as 
well as the gene encoding envelope proteins (Env) from the retroviral genome. This can be achieved 
by the so-called split packaging design (Figure 3). The result is a retroviral vector, which still contains 
the packaging signal (), the primer binding site (PBS) and the long terminal repeats (LTR), but 
harbors the transgene instead of genes encoding for structural and enzymatic retroviral proteins. The 
viral Gag/Pol and Env proteins are encoded on separate helper expression plasmids, which lack all 
other retroviral components including the retroviral packaging signal, and thus lower the probability of 
recombination events. In contrast to HIV-1 or Foamy virus, the gammaretroviral packaging system 
does not require the incorporation of any sequences overlapping with coding sequences of gag, pol or 
accessory genes [10,11,65,66]. Moreover, the gammaretroviral leader sequence of the vector has been 
liberated from ATG initiating potential ORFs, which minimizes the risk to produce immunogenic 
peptides derived from the pre-canonical translational initiation [66–68]. 
Figure 3. From the virus to the vector. The general genome structure (see Figure 1) is 
depicted above with LTRs, packaging signal  and the open reading frames for structural 
proteins  (gag),  replication  enzymes  (pol)  and  envelope  glycoproteins  (env).  For 
construction  of  a  gene  transfer  tool,  the  cis-acting  elements  (LTRs  and  leader  region  
with  )  and  the  open  reading  frames  for  gag/pol  and  env  are  divided  onto  separate 
plasmids. Gag/pol and env are placed in a heterologous DNA context (Prom: promoter; 
pA: polyA signal) that can be delivered as a plasmid transiently or stably inserted into the 
host cell DNA of the packaging cell. The gag/pol and env plasmids lack , so that the 
encoded  RNA  cannot  be  packaged  into  retroviral  particles.  In  contrast  to  the  helper 
plasmids, the vector DNA containing gene of interest (GOI, e.g., a therapeutic transgene 
cassette), flanked by the LTRs, harbors  for efficient packaging into the viral particle. 
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Conventional  retroviral  vectors  are  driven  by  the  promoter/enhancer  sequences  of  the  5’  LTR  
(so-called LTR-driven vectors). Within the U3 region the enhancer/promoter sequences are tightly 
clustered  (e.g.,  various  transcription  factor  binding  sites,  CAAT  and  TATA  boxes)  resulting  in 
relatively  strong  U3  promoters.  However,  compared  to  the  standard  Moloney  MLV  sequences, 
improved variants, e.g., derived from Spleen-Focus Forming Virus (SFFV) and Myeloproliferative 
Sarcoma  Virus  (MPSV),  could  be  generated  which  show  higher  gene  expression  in  a  variety  of 
somatic cells, and especially hematopoietic cells [66,69–71]. 
In the leader region, the natural splice donor (located at the foot of a large R-U5 loop secondary 
structure [25,72]) together with the env splice acceptor placed after the packaging signal  can be 
exploited to create a conditional intron (which is transferred into target cells because of the presence of 
as originally proposed by Mulligan, Miller and colleagues in the MFG and LN vector designs 
[73,74]. It could be demonstrated that presence of an intronic sequence in the leader region had a 
beneficial effect on transgene expression [66], probably because introns can facilitate mRNA export 
and translatability of the retroviral RNA in target cells [71,75]. As an alternative explanation, the 
splicing within the retroviral leader removes possibly disturbing RNA secondary structures, which 
might hamper gene expression and translatability. 
The leader does not just only contain , splice signals and secondary structures but also the PBS to 
which a cellular tRNA molecule binds to initiate reverse transcription (see above). Interestingly, the 
PBS is also the target of innate immunity and is has been a long mystery as to why the PBS is involved 
in silencing of retroviral expression in embryonic stem cells and also in some somatic cells. Only 
recently the underlying cause for this silencing mechanism has been elucidated [76,77], pointing to a 
broader picture of antiviral immunity in primitive stem cells [78]. Wolf and Goff could show that a 
protein  complex  binding  to  the  wild-type  PBS  of  MLV  is  responsible.  This  complex  consists  of 
TRIM28  (Kap-1),  a  well-known  transcriptional  silencer,  working  in  concert  with  the  zinc  finger 
protein ZFP809 bridging proviral DNA and TRIM28. Substitution of this wild-type PBS with a PBS 
binding the tRNA
Gln (instead of tRNA
Pro), derived from an endogenous retroviral sequence (dl587rev), 
led to new gammaretroviral vectors which are less prone to silencing in embryonic stem cells and 
other somatic cell types [69,79–81]. Another interesting principle involving the PBS is the usage of an 
artificial  PBS  (aPBS),  which  does  not  match  any  natural  occurring  tRNA  molecule  (see  also  
Section 7). Transcomplementation with the matching tRNA primer creates a switch for initiation of 
reverse transcription and therefore might be used as a safety feature [82]. 
For the production of gammaretroviral vector particles, both Gag/Pol and Env proteins as well as 
the retroviral vector construct are either transiently or stably co-expressed in so-called ―packaging cell 
lines‖ (e.g., human embryonic kidney derived 293T cells). Since gag/pol and env expression constructs 
lack , viral structural proteins only recognize the -containing retroviral vector construct leading to a 
preferential packaging of retroviral vector genomes into infectious particles. After entry of the particle 
into the target cell, only the nucleic acid of the retroviral vector construct is reverse transcribed and 
stably integrated into the host genome. Since gag/pol and env are only transferred in the form of 
proteins (and not as nucleic acid) the generation of replication competent retroviral vector progeny is 
prevented.  
Limitations of gammaretroviral vectors may arise from the poor infection of non-dividing cells, 
faulty  reverse  transcription,  intracellular  restriction  factors  [83,84]  and  the  risk  of  insertional Viruses 2011, 3                         
 
 
684 
mutagenesis [85–87] (see also below). Life-cycle related constraints may limit vector design, e.g., the 
expression  cassette  should  be  without  introns  (with  the  exception  of  the  leader)  or  internal 
polyadenlyation signals and larger secondary structures or repetitive sequences should be avoided 
because of a possible interference with reverse transcription. Although long expression cassettes (up to 
10 kb) can be incorporated into retroviral vectors [69,88,89], it should be noted that the size of an 
insert is generally a complicating factor for retroviral transgene expression and titer. Moreover, it is 
important to consider that the chromatin architecture and activity as well as epigenetic modifications in 
the vicinity of the integration site might influence vector performance [90], and might thus require 
future optimization of the expression cassette [91]. 
4. Pseudotyping of Retroviral Vectors for Targeting Approaches  
As described above, retroviruses enter cells by taking advantage of a defined envelope/host cell 
receptor  interaction  which  not  only  mediates  specificity  but  also  restricts  the  virus  to  a  limited 
spectrum  of  permissive  target  cells  and  species.  This  behavior  can  be  exploited  for  targeting 
approaches, which are summarized in this section (see below and Table 1).  
Nature created at least three different strains of MLV that basically share, with respect to gag and 
pol, the same genome sequence but strongly differ in their envelope proteins. This implies that among 
the viral proteins,  the envelope might have been the one with the least requirement for sequence 
maintenance or, from another point of view, the one with the highest evolutionary pressure to adapt to 
new  virus—host  cell  interactions.  While  ecotropic  MLV  binds  to  the  murine  cationic  amino  acid 
transporter (mCAT), amphotropic MLV interacts with a sodium-dependent Pi transporter (PiT2), and 
xenotropic MLV gains access to the cell cytoplasm via the XPR1 receptor (xenotropic and polytropic 
retrovirus  receptor  1)  [92–94].  Based  on  these  interactions,  the  first  envelope  only  mediates 
transduction of murine and rat cells while the latter two facilitate transduction of a broader species 
spectrum including humans. 
This example shows two interesting observations. (1) Target cell tropism is mediated by the virus 
envelope and (2) the same virus can be equipped with different envelopes and thus acquires different 
tropisms. In the context of vector development and gene therapy, the exchange of the natural envelope 
protein of any given virus/vector—so-called pseudotyping—is of great importance for the efficacy of 
gene transfer since it allows to choose the optimal envelope for a certain application. As a rule of 
thumb, the pseudotype should be chosen according to the expression level of its receptor on the target 
cell: the higher the receptor level, the higher the gene transfer rate. Consequently, human HSCs can 
easily be transduced with RD114 (a simian endogenous retrovirus) pseudotyped viruses [95], while 
amphotropic viruses or viruses equipped with the envelope of Gibbon Ape Leukemia Virus (GALV), 
both binding to phosphate transporters (PiT2 and PiT1, respectively) show higher transduction rates of 
more  mature  hematopoietic  cells  [96–98].  Despite  their  suboptimal  performance  on  human  HSC, 
ampho  and  GaLV  pseudotyped  MLV  were  successfully  used  in  an  X-SCID  gene  therapy  trial 
conducted in Paris and London (see below). 
The sixth important pseudotype is the glycoprotein (G) of Vesicular stomatitis virus (VSVg). This 
envelope  has  got  several  advantages  over  the  others  in  that  it  is  very  stable  and  thus  allows  for 
concentration of viral particles by high speed ultracentrifugation [99]. In contrast to RD114, GaLV and Viruses 2011, 3                         
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other pseudotypes, VSVg can also be efficiently used for pseudotyping of retroviral vectors other than 
MLV without the requirement for additional modifications of its cytoplasmic tail [100–102]. Although 
VSVg transduces a variety of cells from different species, its application in humans is limited by its 
sensitivity to complement inactivation when systemically applied [100]. In the future, it will be of 
importance to develop improved in vivo gene transfer strategies, not only to expand therapeutic cancer 
intervention but also to facilitate gene therapy of organs that cannot be modified by ex vivo gene 
therapy (e.g., the heart). The feasibility of in vivo cancer gene therapy was recently tested in phase I/II 
clinical studies with a pathotropic (an envelope that recognizes diseased cells) retrovirus for targeted 
killing of transduced cells [103,104]. Although systemic application of this vector seemed to be safe, it 
was restricted to natural targets of von Willebrand factor whose matrix binding elements had been 
incorporated  into  the  ecotropic  MLV  envelope.  An  alternative  targeting  strategy  is  derived  from 
modified  measles  virus  envelopes.  Their  unique  feature  is  the  separation  of  the  receptor  binding  
(H; hemagglutinin) and fusion (F) function to two envelope subunits. Although H of wild-type measles 
virus binds to SLAM/CD150, a surface molecule expressed on lymphocytes, ―blinding‖ of H for its 
receptor  in  combination  with  incorporation  of  a  specific  targeting  domain  (e.g.,  a  single  chain 
antibody)  mediates  cell  type  specific  transduction  [105–107].  This  offers  a  greater  freedom  over 
previously described targeting strategies [103,108,109]. It will be interesting to see to what extent this 
kind of newly evolving targeting technology will boost the in vivo application of gene therapy.  
Table 1. List of most important pseudotypes, their receptors and envelope modifications 
required for pseudotyping of MLV to transduce certain target cells / species. 
Pseudotype  Abbreviation  Receptor  Modification  Target Species  References 
Ecotropic MLV env  Eco  mCAT  not required  mouse and rat  [110] 
Amphotropic MLV env  Ampho  PiT2  not required  multiple  [110] 
Xenotropic MLV env  Xeno  XPR1  not required  human and others  [98] 
Vesicular Stomatitis 
Virus glycoprotein 
VSVg 
not 
determined 
not required  multiple  [111] 
Simian Endogenous 
Retrovirus env 
RD114  RDR/ASCT2  not required  human and others  [112] 
Gibbon Ape Leukemia 
Virus env 
GALV  PiT1  not required  human and ape  [98] 
Measles Virus (vaccine 
strain) H and F proteins 
MV 
CD150, 
CD46 
not determined  human  [113] 
Human 
Immunodeficiency Virus 
gp120 env 
HIV 
CD4 and  
co-receptor 
C-terminal 
truncation 
human  [114] 
 
In addition to the aforementioned pseudotypes, it is of note that MLV could also be equipped with 
envelopes of Hepatitis B virus [115], Lymphocytic Choriomeningitis Virus (LCMV) [116] and others, 
which shows, although this list is by far not complete, the wide spectrum of pseudotypes suitable for 
MLV production. Viruses 2011, 3                         
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5. SIN Design and other Vector Modules 
Although the generation of LTR driven vectors was a milestone in terms of vector development, 
this architecture was still not optimal, because it harbored two promoters and no option to modulate 
gene  expression.  As  a  consequence,  Eli  Gilboa  and  colleagues  developed  the  first  retroviral  SIN  
(self-inactivating) vector in 1986 [117]. Low vector titers could only be overcome by the replacement 
of  the  5’  U3  region  with  strong  promoters  (needed  in  the  packaging  cell  line)  derived  from 
Cytomegalovirus or RSV. Titers could further be increased by adding an SV40 enhancer upstream of 
the  RSV  promoter  and  by  inclusion  of a  post-transcriptional regulatory element derived from the 
woodchuck hepatitis virus upstream of the 3’ SIN LTR [13,56,118]. SIN vectors harbor a deletion 
within the 3’ U3 region initially comprising enhancer/promoter activity. During reverse transcription, 
this deletion is copied to the 5’ LTR, depriving the provirus from LTR-located promoter activity and 
thus conferring transcriptional control to an internal promoter of choice (see Figure 4). The SIN design 
has multiple advantages. First, it reduces the risk of RCR formation, impedes the mobilization of 
vector  sequences  in  case  of  wild-type  virus  infection  or  RCR  superinfection  and  increases  the 
autonomy of the internal promoter. Second, the deletion of the promoter /enhancer elements and the 
incorporation of a cellular (more physiological) internal promoter create safer vector tools and reduce 
the risk of insertional upregulation of neighboring genes (see Section 6 below). Third, the choice of the 
internal promoters can be made according to specific requirements of gene expression needed for a 
given application (e.g., tissue-/lineage-specific or regulated). In order to maximize gene expression 
and therapeutic outcome, early generation SIN vectors often made use of strong ubiquitously active 
viral promoters. Later generations focused on utilizing weaker (cellular) promoters in combination 
with  codon-optimized  transgene  cassettes  (see  below)  to  compromise  between  genotoxicity  and 
expression intensity. As an alternative, a subset of retroviral promoters,  e.g., derived from human 
endogenous  retroviruses  (HERV)  can  also  be  utilized  that  have  evolved  as  transcriptional  control 
elements for cellular gene expression and differ widely in activity and tissue specificity [119].  
In  addition  to  transcriptional  control  by  cell  type  or  lineage  specific  promoters,  transgene 
expression can be regulated on the posttranscriptional level. An important concept is the incorporation 
of repeats of microRNA target sites into the transgene harboring retroviral RNA [120,121]. In this 
way, cells which express the corresponding microRNA downregulate transgene expression. Potential 
applications include ―posttranscriptional detargeting‖ from antigen-presenting cells or hematopoietic 
stem cells [122,123]. On the other hand, retroviral transcripts can also be stabilized. The incorporation 
of the woodchuck posttranscriptional regulatory element (wPRE) increases mRNA stability, mRNA 
export and translatability [71,118,124]. Also the codon optimization of the transgene sequence goes 
along these lines and increases mRNA stability and translatability of the retroviral RNA [125,126]. A 
third  possibility  to  increase  gene  expression  from  retroviral  transcripts  is  to  improve  their 
polyadenylation. Due to the compact structure and the redundancy of the LTRs, orthoretroviruses have 
relatively weak polyadenylation signals [127]. Their polyadenylation efficiency further decreases in 
SIN vectors, where parts of the U3 regions, which have been shown to stimulate polyadenylation, are 
deleted [128]. Interestingly, upstream polyadenylation enhancer sequences (USE elements) have also 
been identified in other viruses (e.g., SV40), and can thus be incorporated into retroviral vectors to Viruses 2011, 3                         
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enhance their polyadenylation efficiency [129], possibly by recruiting more polyadenylation factors to 
the correct polyA site. 
Figure 4. Schema of a gammaretroviral LTR-driven vector (a) and a SIN (self-inactivating) 
vector (b). The upper part shows the plasmid configurations along with the corresponding 
transcripts originating from either the internal promoter (Prom; b) and/or the LTR (a and 
b). The lower part depicts the vector architecture after reverse transcription (RT; i.e., in the 
integrated form). Note that the promoter from the 3’LTR in the plasmid configuration is 
copied into the 5’LTR during reverse transcription facilitating the duplication of either SIN 
deleted U3 (U3) or regular U3 promoter sequences. The corresponding RNAs (with Cap 
and  polyA)  are  depicted  under  the  vector  diagrams  (color  codings  indicating  the 
appropriate promoter). 
 
 
Taken together, the generation of SIN vectors and improvement of their post-transcriptional gene 
expression  allow  usage  of  weaker  internal  promoters.  Thereby,  this  vector  family  creates  a  more 
efficient and possibly also safer tool for gene therapy (see also Section 6 and outlook). However, all 
integrating  vectors  harbor  a  residual  risk  for  insertional  upregulation  of  neighboring  alleles  or 
disruption of cellular genes. Consequently, non-integrating vectors (which are reviewed in Section 7) 
represent interesting tools for transient retroviral gene transfer avoiding the integration step and thus 
the major risk of insertional transformation. 
6. Towards Clinical Production of Retroviral SIN Vectors 
In general, retroviral vectors can be produced in two ways: transient or stable. In the former the 
vector and helper constructs are delivered transiently as plasmids, while in the latter all components 
are stably integrated into the host cell genome of the packaging cell line. The biggest advantage of 
transient production is that it is more flexible and that it avoids the time consuming process to generate 
stable  vector  producing  packaging  cells.  Special  consideration  of  the  design  of  vectors  and 
corresponding packaging allowed clinical grade vector production with titers of ~10
6–10
7 infectious 
particles/mL [130]. Of note, transient production in 293T cells is also available for other retroviral 
vectors, such as lentiviral SIN vectors. Viruses 2011, 3                         
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In contrast, stable packaging cells are more difficult to be generated, which is still a very hard task 
as for lentiviral vectors, since not all components (e.g., VSV glycoprotein and lentiviral Gag/Pol) are 
well tolerated within the packaging cell line over extended periods of time. Stable packaging cell lines 
for conventional LTR-driven gammaretroviral vectors have been produced. They could be established 
by  transducing  existing  stable  packaging  cell  lines  (e.g.,  PG13  [131],  harboring  gammaretroviral 
gag/pol and GALV env) with LTR-driven gammaretroviral vectors and selection for the best producer 
clones. However, this procedure is not adaptable to gammaretroviral SIN vectors, which are—due to 
the self-inactivating U3—not capable of producing packageable genomic viral RNA in transduced 
packaging cell lines.  
To  circumvent  this  problem,  the  recombinase-mediated  cassette  exchange  technology  (RMCE; 
[132,133] was employed to tag and exchange a highly expressing, open chromatin locus with the 
desired vector construct [88,134]. Here a site-specific recombinase (Flp) was used in concert with two 
heterospecific (non-interacting) Flp recognition sites (FRT) to target the packageable retroviral SIN 
vector construct into the predefined locus. This strategy can produce retroviral SIN vectors with titers 
in the range of 10
5–10
6 infectious particles/mL and proof-of-concept has been demonstrated as for the 
clinically relevant vectors expressing collagen 7 (epidermolysis bullosa; [88]) as well as IL2c (severe 
combined immunodeficiency) and gp91phox (chronic granulomatous disease) [134].  
7. Exploiting Intermediate Steps for Developing Tools for Transient Genetic Manipulations 
For some applications, the transient/short-term expression of a given protein is sufficient or even—
due  to  cytotoxic  side  effects—required.  But  how  can  an  integrating  and  permanent  expressing 
retroviral gene vehicle be turned into a transient expression tool? The knowledge of the retroviral 
replication cycle allows defined interventions avoiding the (potentially harmful) integrating nature of 
retroviruses.  Considering  retroviral  particle  composition  and  steps  within  the  early  phase  of  the 
retroviral life cycle three different possibilities are thinkable: Episomal DNA, delivery of RNA or 
protein (Figure 5). The following section will provide an overview of these different options. 
To date the most common way to achieve sufficient gene expression from retroviral vectors while 
avoiding  their  stable  integration  into  the  host’s  cell  genome  is  the  use  of  gammaretroviral  and 
lentiviral integration-deficient vector particles. In theory, integration can be abrogated by blocking the 
integrase  attachment  site  on  the  viral  LTRs,  using  an  integrase  inhibitor  (e.g.,  raltegravir)  or—as 
mostly used—by modifying the integrase itself. The retroviral integrase consists of an N-terminal zinc 
finger domain followed by a catalytic core domain and a C-terminal DNA-binding domain. In contrast 
to  wild-type  particles,  the  latter  are  packaged  with  Gag/Pol  variants  whose  integrase  has  been 
inactivated  by  the  introduction  of  specific  point  mutations  within  the  DDE  motif  of  its  catalytic 
domain. The DDE motif of the HIV integrase is located at positions D64, D116 and E152 [135], the 
DDE motif of MLV integrase at D125, D184 and E220. Point mutations that result in amino acid 
changes  at  these  positions  specifically  inhibit  integration  but  not  other  intermediate  steps  of  the 
retroviral  life  cycle  (e.g.,  cellular  and  nuclear  entry,  reverse  transcription)  and  result  in 
extrachromosomal (episomal) viral DNA, which may serve as a transient source of transgene expression. 
DNA repair processes form 2-LTR circles, and homologous recombination may lead to 1-LTR circles. 
The most common mutation for lentiviral vector systems is D64V, for which efficient gene expression Viruses 2011, 3                         
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especially  in  non-dividing  cells  (such  a  retina  cells)  could  be  demonstrated  [136,137].  Whereas 
episomes are diluted in rapidly dividing cell populations, expression can last long-term in non-dividing 
cells if the encoded protein is neither toxic nor immunogenic. In analogy, corresponding mutations in 
the DDE motif of the core domain of MLV have been identified (e.g., D184A) [138] and used in non-
integrating  gammaretroviral  vector  systems  [139].  Nevertheless,  these  particles  still  require  cell 
division to mediate transgene expression. However, the destruction of the catalytic core domain of the 
retroviral integrase does not prevent spontaneous integration. Detailed analyses revealed that these 
events  are  based  on  non-homologous  or  homology-driven  integrations  rather  than  mediated  by 
potential residual activity of the mutated viral integrase. Although the frequency of residual integration 
events typically does not exceed 3%, it should be considered that some transient gene therapeutic 
approaches require provirus-free genomes (e.g., the reprogramming procedure and other applications 
including oncogenes). So how can residual integrations be further reduced or even circumvented? Our 
laboratory  developed  gammaretroviral  particles  that  were  modified  to  transduce  either  RNAs 
(retrovirus particle-mediated mRNA transfer, RMT) or proteins (retrovirus particle-mediated protein 
transduction, RPT) into a given target cell [140,141]. The RMT technology takes advantage of the two 
capped and polyadenylated retroviral RNA genomes that are embedded in the retroviral particle. To 
allocate these transcripts resembling cellular mRNAs for translation, reverse transcription needs to be 
blocked  either  by  chemical  intervention  (e.g.,  AZT,  a  reverse  transcriptase  inhibitor)  or  by  the 
inactivation of either reverse transcriptase or the PBS, i.e., the landing platform for the tRNA primer 
initiating RT. For RMT, the incorporation of an artificial PBS (aPBS) not matching any naturally 
occurring tRNA molecule, originally designed as a safety feature of the packaging technology for 
retroviral vectors [82] has been most effective in mediating transient expression of a gene of interest 
from the retroviral transcript. Compared to expression levels from non-integrating episomal vectors, 
RMT mediates more rapid but lower expression, and lacks any residual integration events. Of note,  
in comparison to first generation RMT constructs, improved vector design mediated a further increase 
in  titer  and  expression  allowing  to  establish  a  transient  and  efficient  recombinase  transfer  
technology [142]. 
Another possibility for transient cell modification is the usage of retroviral particles for (ectopic) 
transfer  of proteins. Footprinting  approaches  could identify tolerant sites in  the retroviral genome 
where  coding  sequences  of  heterologous  genes  can  be  incorporated  [143–146].  Taking  into 
consideration that every particle harbors between 3000 to 5000 gag molecules one can imagine the 
expected  heterologous  protein  load.  Tolerant  sites  were  mapped  in  MA,  p12  and  NC,  and  also 
modifications of pol (e.g., IN), the latter with the limitation of only a few dozen molecules being 
incorporated  per  particle,  are  well  tolerated.  This  strategy  also  allows  for  fluorescent  tagging  of 
retroviral  proteins.  Of  note,  the  fusion  to  a  specific  retroviral  protein  couples  the  fate  of  the 
heterologous  protein  to  its  fusion  partner  (including  subcellular  localization  and  degradation).  To 
circumvent this, we introduced an additional protease cleavage site between the protein of interest and 
the retroviral protein. The retroviral protease thus cleaves the protein of interest from the retroviral 
protein during extracellular maturation of the retroviral particles, and after transduction of target cells 
the protein of interest is liberated to follow its designated function. Interestingly, retroviral particles 
can  also  be  labeled  extracellularly  (a  procedure  the  authors  called  ―painting‖)  using  fluorescent 
proteins attached to a modified GPI anchor [147], and serve for cytokine display [148–150].  Viruses 2011, 3                         
 
 
690 
A comparison of RMT, RPT and non-integrating retroviral vectors shows that all techniques have 
advantages  and  disadvantages.  While  non-integrating  episomal  vectors  give  the  most  robust  and 
longest expression, their application is limited by the risk of residual integrations. RMT is especially 
suited for applications where low and transient gene expression mediates a strong phenotype (e.g., the 
application  of  recombinases).  RPT,  in  contrast  to  the  previous  techniques,  transfers  recombinant 
proteins instead of viral nucleic acids, and therefore mediates short-term modification of cells without 
the risk of inducing antiviral immunity against viral genomes. The big advantage of all three retroviral 
options is that they can be targeted via specific receptors. Here it is important to note that the recently 
developed  measles  virus  pseudotypes  [113,151]  allow  cell  specific  targeting  for  lentiviral  and 
gammaretroviral  vectors  through  the  introduction  of  specific  binding  sequence  (e.g.,  single  chain 
antibodies) to the H protein of the measles envelope. 
Figure 5. Retroviral tools for transient genetic manipulation. A color-encoded retroviral 
particle  is  shown.  The  following  3  retroviral  techniques  taking  advantage  of  retroviral 
features are demonstrated. As for RPT (retroviral protein transfer, indicated in green) the 
coding sequence for a protein of interest is embedded into tolerant sites of the gag or pol 
ORF  (e.g.,  MA,  p12,  NC  or  IN).  To  liberate  the  protein  of  interest  during  retroviral 
maturation the protein of interest is flanked by an additional protease site. As for RMT 
(retroviral mRNA transfer, red) the retroviral mRNA is modified by an artificial primer 
binding site not matching any natural occurring tRNA but can still serve as a template for 
immediate translation. The majority of non-integrating retroviral vectors (see blue) have a 
point  mutation  within  the  catalytic  core  domain  of  integrase  (see  structure).  Although 
integration is blocked the retroviral side products 1- and 2-LTR circles (episomal forms) 
can still serve for transient gene expression. 
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8. Clinical Applications and How to Improve Safety 
8.1. Human Gene Therapy: First Steps and Stumbles 
Although retroviral gene therapy only represents ~20% of all gene therapy trials (for a complete 
overview  of  human  gene  therapy  trials  see  [152]),  it  has  a  broad  application  to  fight  all  kinds 
of diseases (see also selection in Table 2). 
One of the preferred targets for retroviral gene therapy is the hematopoietic system. It is maintained 
by a limited number of hematopoietic stem cells (HSC) that reside within the bone marrow, and harbor 
the  potential  to  self-renew  and  differentiate  into  all  blood  lineages  [153].  Under  steady  state 
hematopoiesis, HSC cycle infrequently with extended periods of dormancy between cell divisions, 
which  helps  protecting  their  regenerative  capacity  [154–157].  Under  regenerative  stress,  
e.g.,  chemotherapy,  irradiation  or  after  bone  marrow  transplantation,  repopulating  HSCs  re-enter 
mitosis until their niche is replenished, and normal hematopoiesis is restored [154]. This behavior is 
routinely harnessed in allogenic bone marrow transplantation for the treatment of immunodeficiencies 
or cancer, where CD34
+ cells are purified from the bone marrow or peripheral blood of the donor prior 
to transplantation [158]. 
In fatal blood disorders where no suitable donor is available, infusion of gene corrected autologous 
HSC might be the only treatment option, and requires an additional phase of ex vivo cultivation which 
facilitates  corrective  gene  transfer  [159–162].  Only  recently,  cytokine  cocktails  and  signaling  
pathways have been identified that assist in vitro stem cell proliferation while preserving stemness, 
and might thus increase the success of HSC gene therapy due to enhanced repopulation capacity of the 
graft [163–166].  
In general, gene therapy targeting HSCs involves four major steps: (1) purification and cultivation 
of HSCs, typically in a mixture with more mature progenitor cells, (2) retroviral gene transfer ex vivo, 
typically followed by at least a few hours of cultivation prior to cell harvest, (3) conditioning of the 
patient (unless the gene-modified cells have strong selective advantage), and (4) transplantation of 
gene modified cells. The conditioning protocol is required to create space in the bone marrow of the 
patient so that the newly transplanted cells will engraft into the niches for subsequent multiplication. In 
certain protocols, this step is not included due to the enhanced fitness or a survival advantage of the 
genetically corrected over the diseased stem cells, which will facilitate their engraftment per se. 
Gene therapy for the treatment of monogenetic diseases is only feasible when a justified risk-benefit 
assessment is applied, i.e., when the disease is fatal, no other treatment option is available and efficacy 
and safety have been sufficiently tested in pre-clinical studies [167]. In the context of hematopoietic 
gene therapy, these requirements are fulfilled by a number of diseases that affect the immune system, 
the so-called ―severe combined immune deficiencies‖ (SCID). Common to all SCID patients is an 
impaired immune system, frequent and often chronic infections, and a low life expectancy in the 
absence of suitable bone marrow donors [168]. In SCID-ADA, the second most common form of 
SCID, a single enzyme—adenosine deaminase (ADA)—is malfunctional due to a single autosomal 
gene defect on chromosome 20 that is recessively inherited. As a result of ADA deficiency, cells are 
impaired  in  purine  metabolism  and  subsequently  toxic  levels  of  dATP  accumulate  in  lymphoid 
progenitors and interfere with their maturation, and are responsible for neurologic impairment and Viruses 2011, 3                         
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skeletal abnormalities. Without bone marrow transplantation or bovine PEG-ADA drug replacement 
therapy,  patients  have  a  life  expectancy  of  ~one  year.  Although  PEG-ADA  treatment  mediates 
improved  purine  metabolism  and  thus  increases  the  life  span  of  the  patient,  long-term  immune 
restoration is often not achieved due to the formation of neutralizing antibodies against the enzyme. 
In  1990,  Anderson,  Blaese,  and  Culver  were  the  first  to  test  gene  therapy  in  the  context  of  
SCID-ADA [169]. The disease qualified for this treatment since the addition of a single copy of a 
functional gene into patient derived lymphocytes should alleviate the phenotype. In 1992, Claudio 
Bordignon and co-workers also used retroviral vectors to transfer the ADA gene but this time targeted 
the HSC [170]. In contrast to the first study, where a short lived mature cell population had been 
genetically modified, gene transfer into HSC was supposed to grant long lasting ADA expression in all 
progeny cells. Although the clinical benefit of both studies was rather limited, especially due to low 
gene transfer rates, they proved that retroviral gene transfer into different blood cell types was feasible, 
and gene modified autologous cells would persist in the patient’s blood circulation without causing 
adverse effects. These initial observations paved the way for very successful studies by Aiuti and 
colleagues,  where  nonmyeloablative  bone  marrow  conditioning  facilitated  efficient  engraftment  of 
gene  modified  HSC  [171].  Until  now,  their  study  has  enrolled  more  than  15  patients  that  were 
successfully treated and mainly became independent from PEG-ADA drug therapy. Even 10 years 
after the first patient was treated, no severe adverse effects have been observed so far, which renders 
SCID-ADA an example for the successful development of gene-therapy medicinal products [172]. 
Another successful clinical trial including 20 boys had been initiated for the treatment of SCID-X1 
in Paris and London some 10 years ago [159,160]. In this disease, a gene defect of the X-chromosome 
encoded interleukin  2 common gamma  chain (IL2c), which  is  also  part  of the cytokine receptor 
complex for IL4, IL7, IL9, IL15 and IL21, results in the production of dysfunctional B-cells and the 
complete absence of T- and NK-cells. In 17 of the 20 infant patients, their condition was improved by 
transplantation of autologous gene modified HSC, while older patients, most likely caused by impaired 
thymopoiesis,  did  not  respond  as  well  to  the therapy [159,160,173]. This  might  clearly  argue  for 
therapeutic intervention in juvenile patients.  
After  these  initial  encouraging  results,  five  patients  presented  with  T  cell  acute  lymphoblastic 
leukemia  (T-ALL)  two  to  six  years  after  therapy,  with  vector  integrations  in  the  vicinity  of  well 
characterized proto-oncogenes [86,174]. Similar adverse events were observed in two additional gene 
therapy trials for X-chromosome linked chronic granulomatous disease (X-CGD) and Wiskott-Aldrich 
syndrome (WAS). 
CGD patients suffer from chronic infections due to the genetic deficiencies in proteins belonging to 
the  NADPH oxidase  complex, which  is responsible to  produce  reactive oxygen  species  (ROS) in 
phagocytic cells. As a result, engulfed pathogens are not destroyed by ROS but persist as intracellular 
parasites protected from immune recognition. Therefore, CGD patients require permanent antibiotic 
and antimycotic prophylaxis to minimize periods of life threatening infections. In order to restore 
immune competence in patients lacking suitable bone marrow donors, autologous HSC have been gene 
corrected to restore expression of gp91phox, a protein defective in a X-linked form of CGD [161]. 
Patients experienced a (transient) therapeutic effect. However, in a clinical trial using an LTR-driven 
gammaretroviral vector, progressive silencing of the transgene cassette compromised the therapeutic Viruses 2011, 3                         
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effects,  and  long-term  marking  was  complicated  by  insertional  upregulation  of  the  MDS/EVI1  
proto-oncogene, ultimately inducing a myelodysplastic syndrome [87,161,175]  
In  Wiskott-Aldrich  syndrome,  the  phenotype  is  induced  by  a  lack  of  functional  WAS  protein 
(WASP) expression in lymphocytes resulting in immunodeficiency and thrombocytopenia. Patients not 
qualifying for bone marrow transplantation often succumb to infections or bleedings early in life. In a 
clinical  study  in  Hannover,  Germany,  several  patients  were  transplanted  with  gene  modified 
autologous  HSCs  [162],  and  despite  a  clear  clinical  benefit  and  polyclonal  hematopoiesis,  vector 
induced oncogene upregulation led to T-ALL in one patient [176]. As in the other clinical trials in 
which  severe  adverse  events  were  observed  in  association  with  insertional  proto-oncogene 
upregulation, an LTR-driven gammaretroviral vector was used in this first clinical trial to treat WAS. 
Regardless of a multitude of gene therapy trials aiming to treat hematopoietic disorders, HSC gene 
therapy can also be used to ameliorate neurodegenerative diseases. This has been effectively shown for 
the treatment of X-linked adrenoleukodystrophy (ALD), a disease characterized by destruction of brain 
glial cells and subsequent demyelinization and mental retardation. Patients develop symptoms early in 
life  and  most  often  do  not  survive  their  teens.  ALD  can  be  effectively  treated  by  bone  marrow 
transplantation when early diagnosed, so that monocyte derived cells can replace neuronal microglia in 
the brain before the disease gets untreatable. In a recent clinical study, ALD gene transfer mediated by 
a  lentiviral  SIN  vector  into  autologous  HSC  effectively  restored  glial  cells  in  the  brain  without 
disturbing regular hematopoiesis or the induction of adverse events [177]. However, this lentiviral SIN 
vector used an internal promoter derived from an MLV U3 region, and thus long-term observation may 
be important to monitor the potential emergence of clonal imbalance. The scope of retrovirus mediated 
gene therapy could also be expanded to the treatment of fatal skin disorders. In a recent proof-of-
principle case study, restoration of Laminin 5 expression in keratinocyte stem cells facilitated ex vivo 
expansion of skin patches, and their engraftment on a Epidermolysis bullosa patient who suffered from 
blistering and infections of the skin [89,178]. Transplanted areas remained healthy and significantly 
helped  to  improve  the  condition  of  the  patient.  Remarkably,  in  contrast  to  HSC  gene  therapy, 
transplantation of gene modified skin stem cells might be safer since clonal skin grafts can be analyzed 
prior to  transplantation for suspicious insertion events and can routinely be analyzed for signs of 
cancer after engraftment by visual inspection. 
Based  on  adverse  events  observed  in  dose  controlled  clinical  trials  for  SCID-X1,  X-CGD  and 
WASP, it seems ironic that gene therapy trials with replicating retroviral vectors have been launched. 
These vectors are normally taken to carry killer genes into malignant target cells and help fighting the 
disease. Although encouraging results could be obtained with these vectors [103,104,179], they are 
beyond the scope of this review and will therefore not be discussed to a greater extent. However, they 
clearly show that the use of retroviral vectors as therapeutic agents is constantly expanding and might 
even grow with the increasing understanding of their biology. Viruses 2011, 3                         
 
694 
Table 2. Selected gene therapy trials targeting the hematopoietic system or skin disorders. 
Disease  Phenotype  Affected Gene(s) 
Conventional 
Therapy 
Target 
Cells 
Vector 
Vector 
Related Side 
Effects 
Reference 
Epidermolysis 
bullosa 
Detaching skin and 
mucosal tissues 
Keratin or 
collagen 
Skin graft 
transplantation 
MSC  GV-LTR  n.a.  [89] 
Wiskott- Aldrich 
Syndrome 
Immuno deficiency, 
thombocytopenia and 
blood cancer 
WAS 
Drug therapy and / or 
BM transplantation 
HSC  GV-LTR  Leukemia  [162]  
Chronic 
granulomatous 
disease 
Lack of phagocytic 
lymphocytes 
gp91-phox  BM transplantation  HSC  GV-LTR  Leukemia  [161] 
SCID-X1 
Lack of T and NK 
cells, and of mature B 
cells 
IL2c  BM transplantation  HSC  GV-LTR  Leukemia  [86,159,174,180] 
SCID-ADA 
Immunodeficiency, 
skeletal and 
neurologic 
abnormalities 
Adenosine 
deaminase 
Drug therapy and / or 
BM transplantation 
HSC  GV-LTR  n.a.  [160,181]  
Beta thalassemia  Anemia  Beta-globin  Blood transfusion  HSC  LV-SIN 
Clonal 
dominance 
[182] 
Adrenoleuko-
dystrophy 
Cerebral 
demyelination 
ALD  BM transplantation  HSC  LV-SIN  n.a.  [177] 
Melanoma  Skin cancer  various 
Dissection of the 
tumor, chemo- or 
radiotherapy 
T-cells  GV-LTR  n.a.  [183,184]  
Graft versus host 
disease 
Various  n.a.  Drug therapy  T-cells  GV-LTR  n.a.  [185] 
HIV-Aids  Immunodeficiency  n.a.  HAART 
HSC, T-
cells 
LV-LTR  n.a.  [186] Viruses 2011, 3                         
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8.2. Insertional Mutagenesis 
As mentioned above, clinical trials for X-SCID, X-CGD and WAS have unfortunately shown that 
gene therapy can induce severe adverse effects caused by insertional mutagenesis with subsequent 
accumulation of secondary mutations and unrestricted proliferation of cells [86,87,174]. In the early 
days of gene therapy, addition of new genetic information into the genome of the target cell was 
considered  to  be  safe,  since  malignant  transformation  of  human  cells  should  require  multiple 
sequential fitness enhancing genome alterations [187] (and references therein). The number of vector 
integrations per target cell was kept low to avoid adverse effects [188,189]. However, subsequent 
studies revealed that insertional mutagenesis by a single vector integration in the vicinity of a crucial 
proto-oncogene may  trigger transformation  of cells  by inducing  a clonal selective advantage with 
accelerated  cycling  rates,  ultimately  resulting  in  clonal  expansion  not  obeying  to  environmental 
growth limiting cues. A far more frequent outcome of vector insertion is a mild growth advantage of 
cells that successfully repopulate the host but still obey to homeostatic mechanisms (benign clonal 
dominance) [190]. Of note, benign clonal dominance may also reflect a steady state condition normally 
acquired after transplantation of a limited number of gene-modified HSCs [191].  
In a best case scenario, vector insertions do not influence cell behavior which requires insertions 
ideally to occur in intergenic regions. However, due to the semi-random insertion profile of retroviral 
vectors, selective intergenic insertions may be difficult to obtain: Gammaretroviruses cluster in the 
proximity of the transcriptional start site, CpG islands and DNaseI hypersensitive sites, lentiviruses 
integrate within the whole transcription unit, and alpharetroviruses locate relatively uniformly within 
the whole genome [192–197]. Consequently, deregulation of gene function and activity will greatly 
depend upon the nature of the control elements present in the integrated transgene sequence. For an 
overview of the modes of insertional mutagenesis see Figure 6 and [198].  
8.3. Enhancer Interaction 
Cellular gene expression requires the interplay between promoter and enhancer elements which can 
be  located  more  than  100  kb  away  from  each  other  (reviewed  in  [199]).  Cell  type  specific  gene 
expression is achieved by the binding of specific sets of transcription factors to the enhancer and 
subsequent cis activation of the neighboring promoter(s), which might involve the formation of a DNA 
loop between both elements, facilitating long range interactions. 
Gammaretroviral  vectors  are  prone to mediate insertional mutagenesis by enhancer interactions 
when they integrate in the vicinity of cellular promoters and provide strong enhancer elements that are 
bound  by  ubiquitous  transcription  factors,  and  thus  override  cellular  transcriptional  control 
mechanisms. This mode of action requires the vector to integrate in antisense or sense orientation 5’ or 
3’ to a cellular gene so that the cellular promoter is activated by the viral enhancer located in the 5’ 
LTR which is only active when not transcribed (unlike the 3’ enhancer). As a consequence, cellular 
gene  expression  will  be  augmented,  and  as  in  the  case  of  integrations  close  to  the  promoters  of  
proto-oncogenes like MDS1/Evi1 can lead to malignant transformation [87].  
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Figure  6.  Modes of insertional mutagenesis. (a) Vector insertion in reverse orientation 
upstream  of  a  cellular  gene  leads  to  enhancer-mediated  upregulation  of  cellular  gene 
expression. (b) Integration between the promoter and the first coding exon uncouples the 
cellular  transcription  unit  from  its  promoter  and  facilitates  expression  from  the  viral 
promoter. Read-through the 3’ pA signal of the virus leads to fusion transcripts that can 
either remain unchanged or undergo splicing. (c) Integration into a transcription unit can 
mediate pre-mature termination due to usage of pA signals located within the proviral 
DNA. Green box, cellular promoter; red box, coding exon; LTR, long terminal repeat; 
ATG, start codon; SD, splice donor; SA, splice acceptor; An, pA stretch. 
 
8.4. Promoter Insertion 
Provided vector integration occurs between the promoter and the first coding exon, transcription of 
the cellular gene  will be  uncoupled  from its  promoter,  and  will  instead be governed by the viral  Viruses 2011, 3                         
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5’ LTR. Subsequently, a fusion transcript between the viral and cellular transcription unit is generated 
due to read-through the 3’ pA signal of the viral LTR. The fusion transcript can either contain the 
whole proviral sequence or can be subjected to splicing events between the viral major splice donor 
located upstream of the packaging signal and a splice acceptor site upstream of the host gene start 
codon. In both cases, gene products will contain the whole cellular coding sequence, and will thus give 
rise to an increased amount of full-length proteins [200,201]. 
8.5. Pre-Mature Termination 
In contrast to vector insertions close to transcriptional start sites, insertions within the transcription 
unit might result in truncated transcripts. This is mainly due to the presence of pA signals in the R 
regions (when in sense orientation to the transcribed gene), and also cryptic pA signals in the viral 
enhancer  have  been  identified  (in  antisense).  Truncated  transcripts  frequently  lack  regulatory 
sequences  important  for  mRNA  stability,  or  might  encode  for  hyperactive  or  dominant  negative 
protein  mutants.  In  all  cases  cellular  homeostasis  can  be  impaired,  which  for  example  led  to 
deregulation  of  HMG2A  and  subsequent  clonal  dominance  in  a  recent  gene  therapy  trial  for  
beta-thalassemia [182]. 
Despite the induction of vector mediated leukemic transformation events in at least three different 
gene  therapy  trials  (SCID-X1,  X-CGD  and  WAS)  with  LTR-driven  gammaretroviral  vectors,  the 
number of loci that mediated insertional mutagenesis was rather limited, and therefore resembles the 
integration  preferences  of  the  vector  as  well  as  a  limited  number  of  loci  capable  to  drive 
transformation. In the SCID-X1 trial, four leukemia clones harbored vector insertions in the LMO2 
locus and subsequent increase of its expression, while in a fifth patient the upstream region of the 
CCND2 oncogene was hit [86,174]. A similar LMO2 insertion was found in the leukemia patient from 
the  WAS  trial.  The  insertions  found  in  the  2  patients  from  the  X-CGD  trial  were  located  in 
MDS1/EVI1, PRDM16 or SETBP1 and resulted in a pre-myelodysplastic syndrome in combination 
with the acquisition of monosomy 7 [87,161]. 
In accordance with initial considerations most patients not only harbored vector insertions with 
mutagenic potential but also showed secondary genetic alterations most likely important to facilitate 
malignant transformation. Except for one patient, all patients with T-ALL could be successfully treated 
with conventional chemotherapy. 
It remains elusive why gene therapy for the treatment of SCID-ADA seems to be rather safe, while 
in other diseases insertional mutagenesis led to malignant transformation. One reason might be the 
disease  phenotype  itself.  In  contrast  to  SCID-ADA,  primitive  hematopoietic  or  lymphoid  cells  in  
X-CGD and SCID-X1 may be subjected to increased replication stress and thus be more prone to the 
acquisition of secondary growth promoting mutations.  
Consequently, malignant transformation in gene therapy might depend on insertional mutagenesis 
as well as genetic predisposition and disease background, which underlines the need for better disease 
models and vectors with reduced genotoxicity. Viruses 2011, 3                         
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9. Conclusion and Outlook 
Retroviral gene therapy has proven its effectiveness in a number of recent clinical trials. However, 
the occurrence of leukemia and premyelodyplasia (in otherwise successful) clinical trials reminded us 
that safety of gene therapy with integrating vectors needs to be further improved. In this regard, the 
observed severe adverse events were probably attributable to insertional upregulation of neighboring 
proto-oncogenes  by  the  strong  enhancer/promoter  sequences  of  the  LTRs.  Here  SIN  vectors  with 
carefully chosen internal promoters represent safer alternatives making insertional mutagenesis a less 
likely event [202–204]. Also the use of new cytokine cocktails might be promising to further reduce 
the likelihood of clonal outgrowth [205].  
An important avenue and challenge for gene therapy with integrating (retroviral) vectors will be the 
development  of  better  assays  to  predict  more  precisely  insertional  adverse  events  (including 
upregulation of neighboring genes and also gene disruption), ideally both in cell culture based systems 
[202,206] and small animal models [190,204], to allow a good risk-benefit assessment of the planned 
intervention. 
As a first consequence of the reevaluated risk-benefit analysis in the X-SCID trials, new clinical 
trials will be initiated for SCID-X1 in 2011 as part of a multicenter clinical study in Boston, Los 
Angeles, London and Paris. In this study a gammaretroviral SIN vector with weak enhancer/promoter 
elements (having a reduced likelihood to mediate insertional transformation by enhancer interactions) 
will be used, and vector expression is enhanced by the inclusion of the wPRE in the 3’ untranslated 
region [207]. Another important option to improve vector performance without triggering interactions 
with  neighboring  alleles  is  the  codon-optimization  of  the  therapeutic  cDNA,  thus  improving  
post-transcriptional  mRNA  processing  and  allowing  the  incorporation  of  relatively  weak  but  
tissue-specific  promoters  [126].  Finally,  insulator  elements  could  be  placed  into  the  U3  region,  
to  prevent  long-distance  interactions  originating  from  residual  enhancer  located  in  the  vector  
sequence [208]. 
Although this is a review about gammaretroviral vectors, which—as described here—have clearly 
improved over the recent years and are far away from the conventionally used MLV derived vector, it 
should be noted that vector improvements within this and other family members of the Retroviridae 
have cross-fertilized the general usage of retroviral vectors. The infection of non-dividing cells with 
lentiviral vectors (see review by Cimarelli [209]) is an advantageous feature for infection of slowly or 
nondividing  tissues  of  the  human  body  (e.g.,  neurons  or  hepatocytes,  or  stem  cells  that  remain 
quiescent  in  suboptimal  culture  conditions).  Also  the  consequences  of  insertional  preference  of 
specific family members close to the transcriptional start site (e.g., gammaretroviruses) or within genes 
(e.g.,  lentiviral  vectors)  need  to  be  further  analyzed  and  it  remains  to  be  examined  if  yet  other 
retroviral vectors (e.g., those based upon the alpharetroviral Rous sarcoma virus [19,20] or human 
Foamy virus (see review by Lindemann and Rethwilm [210]), which are less biased in their insertion 
pattern, are beneficial in this regard. Thus, the choice of suitable vector tools should be based on a 
case-by-case risk benefit assessment, taking into account vector evolution, which—despite promising 
developments—is still work in progress. Viruses 2011, 3                         
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